



## Intellectual Property for Life Sciences

Life sciences companies turn to WilmerHale to resolve their most complex intellectual property issues. We draw upon deep experience gained by handling thousands of IP matters across the pharmaceutical, biologic and biosimilar, genomic, biotechnology and medical device sectors. It is our privilege and passion to bring to bear our experience in IP litigation, counseling and prosecution to help these clients protect their hard-earned achievements at each stage of growth.

### PRACTICE AT A GLANCE

- Our IP and IP litigation lawyers are part of a multidisciplinary practice of nearly 200 professionals focusing on a broad array of cutting-edge matters for life sciences clients.
- Our team is bolstered by the academic and industry experience of nearly 100 lawyers and technology specialists with scientific and technical degrees, including more than 50 with degrees in biological and chemical sciences.
- We have robust experience with legal processes specific to the life science industry such as Hatch-Waxman litigation related to drugs listed in the Orange Book, litigation arising from the Biologics Price Competition and Innovation Act (BPCIA) and competitor cases.
- We have served as trial and appellate counsel in life science matters before the district courts throughout the US, the Federal Circuit and the US Supreme Court and the International Trade Commission. Our lawyers also have an outstanding track record in *inter partes* review proceedings (IPRs) representing both Patent owners and petitioners before the Patent Trial and Appeal Board (PTAB).

We provide a comprehensive range of IP counseling and prosecution services, including:

- strategic patent portfolio development and life-cycle management;
- IP diligence in connection with public and private offerings and M&A transactions;
- landscape, freedom-to-operate, patentability, validity and infringement advice; and
- strategic coordination of global contested matters strategies for clients involved in oppositions and litigation across multiple jurisdictions.

**200+**

medical device, biopharma  
and diagnostic company clients

**165+**

ANDA cases handled  
Since 2015

**180+**

life science IPRs handled  
by WilmerHale attorneys



**Biotechnology and Life  
Sciences Firm of the Year**

— *Benchmark Litigation*, 2025

## EXPERIENCE

- Won a significant victory on behalf of **Gilead Sciences** against the Department of Health and Human Services in the Court of Federal Claims when the court found that the government breached three material transfer agreements relating to studies of Gilead’s ground-breaking drug, Truvada®, for HIV prevention.
- Represented **Genentech** in biosimilar patent litigations and related IPR matters involving its \$7 billion-a-year drug, Herceptin®. Our work included five district court litigations, 30 IPRs, and issues arising in international jurisdictions including the European Union, Japan, South Korea and Brazil.
- Obtained a favorable settlement for **AbbVie** with Boehringer Ingelheim in some of the first litigations arising under BPCIA related to the proposed sale of a biosimilar for AbbVie’s \$19 billion-a-year product, Humira®.
- Successfully defended **Memorial Sloan Kettering Institute for Cancer Research** against Errant Gene Therapeutics’ accusations of breach of contract, fraudulent misrepresentation and civil conspiracy to defraud. EGT’s alleged claims related to a patented gene therapy for a rare blood disorder developed by MSK and formerly licensed to EGT.
- Prevailed on behalf of **Ancestry** in a lawsuit brought by 23andMe. The district court judge ruled all asserted patent claims invalid as they were directed to patent ineligible subject matter. A Federal Circuit panel unanimously affirmed.
- Obtained a complete victory for **Bristol-Myers Squibb** and **Pfizer** in what began as one of the largest Hatch-Waxman cases ever filed, with 25 different generic companies as defendants, when the court found the patents covering our clients’ blockbuster drug Eliquis® valid and infringed by all generics challenging them. We also handled related IPR matters.
- Achieved a significant victory for **Astellas** affiliate **OSI Pharmaceuticals** and **Genentech** when the Federal Circuit reversed a PTAB decision holding the relevant patent claims obvious. The decision capped our successful four-year defense of the clients’ patent covering Tarceva®, a blockbuster treatment of non-small cell lung cancer.
- Provide strategic patent counseling and freedom to operate advice to a **clinical-stage biopharmaceutical company** focused on therapies for the treatment of psychiatric and neurological disorders.
- Offer strategic advice and manage worldwide patent prosecution of approximately 2,300 patent applications for **Columbia University’s** Morningside and Medical Center campuses, including prosecuting applications in a wide variety of pharmaceutical areas, medical devices, and high-tech innovation.
- Earned a milestone victory for **Becton Dickinson**, ending an eight-year multi-national patent infringement dispute with Braun Melsungen in US district court, the Federal Circuit, the PTAB and numerous jurisdictions across the globe.

- **Law360:** Named an Intellectual Property Practice Group of the Year in both 2026 and 2024.
- **Chambers USA:** Ranked in Band 1 nationally for IP and life sciences since 2011; named 2024 Intellectual Property Firm of the Year.
- **The National Law Journal:** Named the 2024 Intellectual Property Litigation Department of the Year.
- **The Legal 500 United States:** Named among the top law firms in the country for IP and life sciences each year since 2013.
- **LMG Life Sciences:** Awarded 2022 Hatch Waxman Litigation Firm of the Year; 2020 Impact Case of the Year; named the 2019 IP Firm of the Year; recognized as a leader for patent litigation, IPRs and all-around life sciences work.
- **Managing IP:** Consistently listed as Tier 1 for life sciences; honored as the US Patent Disputes Firm of the Year eight times since 2013.
- **U.S. News and World Report:** Named the 2022 and 2021 Patent Law Firm of the Year and the 2020 Biotechnology Law Firm of the Year.

**“WilmerHale provides flawless execution and high-level strategic thinking, which is well grounded in the biotech industry.”**

— *Chambers USA*

For more information, please contact:

**Mary (Mindy) V. Sooter** — Co-Chair, Intellectual Property Litigation Practice | +1 720 274 3164 | [mindy.sooter@wilmerhale.com](mailto:mindy.sooter@wilmerhale.com)

**Emily R. Whelan** — Chair, Intellectual Property Department | +1 617 526 6567 | [emily.whelan@wilmerhale.com](mailto:emily.whelan@wilmerhale.com)

**Amy K. Wigmore** — Co-Chair, Intellectual Property Litigation Practice | +1 202 663 6096 | [amy.wigmore@wilmerhale.com](mailto:amy.wigmore@wilmerhale.com)

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 2100 Pennsylvania Avenue, NW, Washington, DC 20037, +1 202 663 6000. Our United Kingdom office is operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at [www.sra.org.uk/solicitors/standards-regulations/code-conduct-solicitors/](http://www.sra.org.uk/solicitors/standards-regulations/code-conduct-solicitors/). A list of partners and their professional qualifications is available for inspection at our UK office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2026 Wilmer Cutler Pickering Hale and Dorr LLP